UNITED THERAPEUTICS Corp

North Carolina—We own a total of 279 acres and have active operations in approximately 630,000 square feet at our co-headquarters campus in RTP. Our clinical research and development, commercialization, manufacturing, warehousing and logistics hub, and our ULobe research and development laboratory, all operate within this campus. We manufacture Orenitram drug product and we package, warehouse, and distribute Nebulized Tyvaso, Tyvaso DPI, Remodulin, Orenitram, and Unituxin at this location. If the FDA approves ralinepag, we plan to transfer manufacturing of this product to our RTP campus following commercial launch. We also have an additional capacity for future growth and expansion at this campus. Additionally, we lease approximately 21,000 square feet of office space in Morrisville, North Carolina to house our United Therapeutics Cares patient support program.

Maryland—We own a 415,000 square foot combination laboratory and office building campus in Silver Spring, Maryland that serves as our co-headquarters, is used to manufacture certain of our products, and houses one of ourex vivo lung perfusion centers. Manufacturing activities at this campus include the synthesis of treprostinil, the active ingredient in Tyvaso DPI, Nebulized Tyvaso, and Remodulin, and treprostinil diolamine, the active ingredient in Orenitram, as well as dinutuximab, the active ingredient in Unituxin. We also manufacture Nebulized Tyvaso drug product, Remodulin drug product, and Unituxin drug product at our Silver Spring campus. We plan to produce manufactured lung alternatives for clinical studies at our Silver Spring campus.

Minnesota—Our Miromatrix subsidiary leases a 42,300 square foot office and laboratory facility in Eden Prairie, Minnesota, where it produces manufactured kidney and liver products for research and development purposes and clinical trials. We are constructing a 65,000 square foot clinical-scale DPF facility in Stewartville, Minnesota where we intend to produce porcine hearts and kidneys for use in xenotransplantation clinical trials and to support eventual commercial production of our xeno-organs following FDA approval.

Florida—We own a 75,000 square foot building on land we lease on the Mayo Clinic campus in Jacksonville, Florida, which houses one of ourex vivo lung perfusion centers. We also own a 14,000 square foot building in Melbourne, Florida, which houses a call center.

New Hampshire—We lease a 74,500 square foot office and laboratory facility in Manchester, New Hampshire, where we conduct our 3D organ alternative bioprinting research and development activities.

Texas—We are constructing a 65,000 square foot clinical scale DPF facility in Houston, Texas, where we intend to produce porcine hearts and kidneys for use in xenotransplantation clinical trials, and to support eventual commercial production of our xeno-organs following FDA approval.

Virginia—We own and operate a 65,000 square foot clinical-scale DPF facility in Christiansburg, Virginia where we produce porcine hearts and kidneys for use in xenotransplantation clinical trials, and where we intend to support eventual commercial production of our xeno-organs following FDA approval. We also lease a laboratory and farm in Blacksburg, Virginia that support our xenotransplantation research and development efforts.

Quebec—We own a 23,000 square foot facility in Bromont, Quebec, Canada, which is dedicated to the development of sustainable aircraft for the delivery of manufactured organs and organ alternatives.

Massachusetts—Our IVIVA subsidiary leases a 23,500 square foot office and laboratory facility in Medford, Massachusetts, where it produces manufactured kidney alternative products for research and development purposes and clinical trials. In 2025, we purchased a 50,000 square foot facility in Lexington, Massachusetts, which is intended to serve as a cGMP site for clinical production of manufactured organs.

We believe that these facilities, along with various other owned and leased facilities, are adequate for our current operations and that additional land and facilities for future expansion are reasonably available.